Astellas Pharma (ALPMY) News Today $10.10 +0.19 (+1.92%) As of 05/2/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Above 50-Day Moving Average - Here's What HappenedAstellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above 50-Day Moving Average - What's Next?May 4 at 7:27 AM | marketbeat.comAstellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual CongressesMay 1 at 9:00 AM | prnewswire.comAstellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call TranscriptApril 28, 2025 | seekingalpha.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Decreases By 98.5%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant drop in short interest in April. As of April 15th, there was short interest totalling 900 shares, a drop of 98.5% from the March 31st total of 60,400 shares. Based on an average trading volume of 885,400 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.April 28, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPSAstellas Pharma (OTCMKTS:ALPMY - Get Free Report) posted its quarterly earnings results on Friday. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.12. The business had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%.April 28, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Stock Crosses Above 50-Day Moving Average - What's Next?Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Above 50 Day Moving Average - Here's What HappenedApril 25, 2025 | marketbeat.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest UpdateAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 60,400 shares, an increase of 144.5% from the March 15th total of 24,700 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 164,900 shares, the short-interest ratio is presently 0.4 days.April 16, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Sets New 1-Year Low - Here's WhyAstellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week Low - Time to Sell?April 12, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month Low - Here's What HappenedAstellas Pharma (OTCMKTS:ALPMY) Hits New 52-Week Low - Here's WhyApril 8, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week Low - What's Next?Astellas Pharma (OTCMKTS:ALPMY) Hits New 1-Year Low - Time to Sell?April 6, 2025 | marketbeat.comAstellas Pharma and JFCR partner for oncology researchApril 3, 2025 | msn.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 56.7% in MarchAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 24,700 shares, a decrease of 56.7% from the February 28th total of 57,000 shares. Based on an average daily trading volume, of 198,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short.March 28, 2025 | marketbeat.comAstellas Pharma (OTCMKTS:ALPMY) Shares Pass Above 50-Day Moving Average - Here's What HappenedAstellas Pharma (OTCMKTS:ALPMY) Shares Pass Above 50-Day Moving Average - Time to Sell?March 26, 2025 | marketbeat.comSinglera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT MeetingMarch 24, 2025 | globenewswire.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Rises By 20.8%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 57,000 shares, an increase of 20.8% from the February 13th total of 47,200 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 225,700 shares, the days-to-cover ratio is presently 0.3 days.March 18, 2025 | marketbeat.comAstellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline ForwardMarch 15, 2025 | seekingalpha.comAstellas Pharma (OTCMKTS:ALPMY) Stock Passes Above 50-Day Moving Average - Should You Sell?Astellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Above Fifty Day Moving Average - Time to Sell?March 11, 2025 | marketbeat.comJ.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)March 8, 2025 | markets.businessinsider.comAstellas and Yaskawa form JV for cell therapy product manufactureMarch 7, 2025 | finance.yahoo.comAstellas and YASKAWA form JV focused on cell therapy manufacturingMarch 6, 2025 | msn.comAstellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy ManufacturingMarch 6, 2025 | finance.yahoo.comAstellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below 200-Day Moving Average - Here's WhyAstellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?March 2, 2025 | marketbeat.comAstellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator PrizeFebruary 27, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?Astellas Pharma (OTCMKTS:ALPMY) Shares Pass Below 200-Day Moving Average - What's Next?February 22, 2025 | marketbeat.comAstellas Pharma Inc.: U.S. FDA Approves Expanded Label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic AtrophyFebruary 13, 2025 | finanznachrichten.deShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 132.4%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large growth in short interest in January. As of January 31st, there was short interest totalling 92,500 shares, a growth of 132.4% from the January 15th total of 39,800 shares. Based on an average daily trading volume, of 497,000 shares, the short-interest ratio is presently 0.2 days.February 13, 2025 | marketbeat.comU.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic AtrophyFebruary 12, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Below 50 Day Moving Average - Here's WhyAstellas Pharma (OTCMKTS:ALPMY) Shares Pass Below 50 Day Moving Average - What's Next?February 12, 2025 | marketbeat.comPfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. ChemoFebruary 11, 2025 | finance.yahoo.comAstellas seeks conditional approval for GA treatment in JapanFebruary 5, 2025 | finance.yahoo.comAstellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In JapanFebruary 5, 2025 | markets.businessinsider.comAstellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in JapanFebruary 5, 2025 | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) Releases Earnings ResultsAstellas Pharma (OTCMKTS:ALPMY - Get Free Report) released its quarterly earnings data on Tuesday. The company reported $0.30 EPS for the quarter. Astellas Pharma had a return on equity of 10.40% and a net margin of 3.26%.February 4, 2025 | marketbeat.comAstellas Makes Announcement about Management StructureFebruary 4, 2025 | prnewswire.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 39,800 shares, an increase of 26.3% from the December 31st total of 31,500 shares. Based on an average daily trading volume, of 569,300 shares, the days-to-cover ratio is currently 0.1 days.February 1, 2025 | marketbeat.comJefferies Reaffirms Their Hold Rating on Astellas Pharma (ALPMF)January 25, 2025 | markets.businessinsider.comAstellas Pharma (OTCMKTS:ALPMY) Hits New 12-Month Low - Here's What HappenedAstellas Pharma (OTCMKTS:ALPMY) Reaches New 52-Week Low - What's Next?January 24, 2025 | marketbeat.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 58.7%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 15th total of 76,200 shares. Based on an average daily volume of 787,700 shares, the days-to-cover ratio is presently 0.0 days.January 14, 2025 | marketbeat.comFDA Accepts Astellas Pharma's Revised SNDA For IZERVAY In Geographic Atrophy TreatmentJanuary 9, 2025 | markets.businessinsider.comAstellas Pharma : China's NMPA Approves VYLOY For Advanced Gastric/Gastroesophageal Junction CancerJanuary 5, 2025 | markets.businessinsider.comShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Increases By 150.7%Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 76,200 shares, an increase of 150.7% from the November 30th total of 30,400 shares. Based on an average daily volume of 559,900 shares, the days-to-cover ratio is currently 0.1 days.December 27, 2024 | marketbeat.comAxcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein DegradersDecember 25, 2024 | businesswire.comAstellas and Sangamo sign capsid deal for neurological diseasesDecember 20, 2024 | msn.comAstellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below 200-Day Moving Average - What's Next?Astellas Pharma (OTCMKTS:ALPMY) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?December 19, 2024 | marketbeat.comAstellas In Deal With Sangamo For STAC-BBB Capsid To Deliver Genomic MedicinesDecember 19, 2024 | markets.businessinsider.comAstellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for ThemselvesDecember 5, 2024 | prnewswire.comAstellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementNovember 20, 2024 | prnewswire.comAstellas Faces FDA Setback on IZERVAY ApplicationNovember 18, 2024 | markets.businessinsider.comAstellas Pharma H1 Profit Rises; Lifts FY24 OutlookOctober 30, 2024 | markets.businessinsider.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short InterestAstellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 45,100 shares, an increase of 16.2% from the September 30th total of 38,800 shares. Based on an average trading volume of 182,400 shares, the days-to-cover ratio is presently 0.2 days.October 29, 2024 | marketbeat.com Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Media Mentions By Week ALPMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPMY News Sentiment▼0.840.73▲Average Medical News Sentiment ALPMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPMY Articles This Week▼51▲ALPMY Articles Average Week Get Astellas Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CSLLY News Today ZTS News Today REGN News Today DSNKY News Today TAK News Today ALNY News Today UCBJY News Today UCBJF News Today BAYRY News Today ONC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ALPMY) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALPMY Stock Free ALPMY Stock Alerts